-
公开(公告)号：US09897612B2
公开(公告)日：2018-02-20
申请号：US14822335
申请日：2015-08-10
Applicant: Janssen Biotech, Inc.
Inventor： Michael Diem , Steven Jacobs
CPC classification number: G01N33/6845 , C12N15/1044 , C40B30/04 , C40B40/08 , C40B50/06 , G01N2333/78
Abstract: Protein scaffolds and scaffold libraries based on a fibronectin type III (FN3) repeat with an alternative binding surface design, isolated nucleic acids encoding the protein scaffolds, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
-
152.发明申请公开(公告)号：US20180036379A1
公开(公告)日：2018-02-08
申请号：US15471790
申请日：2017-03-28
Applicant: Janssen Biotech, Inc.
Inventor： Marc Chevrier , Kamyar Farahi , Newman Yeilding
IPC: A61K38/20 , C07K16/24 , A61K39/00 , A61K39/395 , A01K67/027 , C07K14/54
Abstract: A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.
-
公开(公告)号：US20180036336A1
公开(公告)日：2018-02-08
申请号：US15662706
申请日：2017-07-28
Applicant: Janssen Biotech, Inc.
Inventor： Fei Huang , Joshua J. Rusbuldt , Aleksandra Rizo
IPC: A61K31/7125 , A61K31/496
CPC classification number: A61K31/7125 , A61K31/496 , A61K31/635 , A61K45/06 , A61K2300/00
Abstract: The present invention relates to a combination treatment for hematological cancers. More specifically; a combination of a telomerase inhibitor and a Bcl-2 inhibitor are useful in treating hematological cancers, including AML. In certain embodiments, the telomerase inhibitor is imetelstat or imetelstat sodium and the Bcl-2 inhibitor is ABT-199.
-
154.发明申请公开(公告)号：US20170360607A1
公开(公告)日：2017-12-21
申请号：US15609386
申请日：2017-05-31
Applicant: Janssen Biotech, Inc.
Inventor： Daniel W. Price , Brendan J. Oberkircher , Daniel J. Prenger , Geoffrey King , Thomas E. Meyer , Benjamin L. Ko
CPC classification number: A61F9/00736 , A61B2017/3405 , A61F9/0008 , A61F9/007 , A61M5/20 , A61M5/24
Abstract: An apparatus includes an injector, a first fluid conduit, a second fluid line, and a control module. The injector includes a body, a flexible cannula, a flexible needle, and a sensor. The needle is configured to translate relative to the cannula. The sensor is operable to detect a position of the needle relative to the cannula. The first and second fluid lines are coupled with the needle. The control module is in communication with the sensor, with the first fluid conduit, and with the second fluid conduit. The control module is configured to provide delivery of a first fluid through the first conduit to the needle based on a signal from the sensor. The control module is further configured to provide delivery of a second fluid through the second conduit to the needle.
-
公开(公告)号：US20170360606A1
公开(公告)日：2017-12-21
申请号：US15609457
申请日：2017-05-31
Applicant: Janssen Biotech, Inc.
Inventor： Daniel W. Price , Brendan J. Oberkircher , James G. Lee , Clinton Denlinger , Daniel J. Prenger , Geoffrey King , Scott Uhland , Mark C. Tsai , Michael F. Keane , Isaac J. Khan , Benjamin L. Ko , Thomas E. Meyer , Denis P. Turner
IPC: A61F9/00
Abstract: An apparatus includes a pad assembly, an injector assembly, an injector driver, and a fluid source. The pad assembly is sized and configured to be placed on a forehead of a patient. The injector assembly includes a body, a flexible cannula, and a needle. The body is configured to be removably secured to the pad assembly. The cannula is sized to be inserted through an incision in an eye of a patient. The needle is slidably disposed in the cannula. The injector driver is operable to drive the needle longitudinally relative to the flexible cannula. The fluid source assembly is in fluid communication with the needle.
-
Patent Agency Ranking
公开(公告)号：US09845460B2
公开(公告)日：2017-12-19
申请号：US14085068
申请日：2013-11-20
Applicant: Janssen Biotech, Inc.
Inventor： Janet Davis , Jiajian Liu
IPC: A61K31/00 , C12N5/02 , C12N5/08 , C12N5/071 , C12N5/0735
CPC classification number: C12N5/0676 , A61K31/00 , C12N5/0606 , C12N2501/105 , C12N2501/115 , C12N2501/117 , C12N2501/119 , C12N2501/16 , C12N2501/415 , C12N2501/48 , C12N2501/70 , C12N2506/00 , C12N2506/02
Abstract: The present invention is provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3β (GSK-3B) enzyme activity.
-
公开(公告)号：US20170355963A1
公开(公告)日：2017-12-14
申请号：US15683594
申请日：2017-08-22
Applicant: Janssen Biotech, Inc.
Inventor： Alireza Rezania , Benjamin Fryer
IPC: C12N5/071
Abstract: The present invention provides a method for increasing the expression of MAFA in cells expressing markers characteristic of the pancreatic endocrine lineage comprising the steps of culturing the cells expressing markers characteristic of the pancreatic endocrine lineage in medium comprising a sufficient amount of a cyclin-dependent kinase inhibitor to cause an increase in expression of MAFA.
-
公开(公告)号：US20170290912A1
公开(公告)日：2017-10-12
申请号：US15626697
申请日：2017-06-19
Applicant: Janssen Biotech, Inc.
Inventor： Jacqueline Benson , Mark Cunningham , Cynthia Duchala , Jill Giles-Komar , Jinquan Luo , Michael Rycyzyn , Raymond Sweet
IPC: A61K39/395 , A61K45/06
CPC classification number: A61K39/3955 , A61K39/00 , A61K45/06 , A61K2039/505 , A61K2039/55527 , A61K2039/55544 , C07K16/244 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/55 , G01N33/6869 , G01N2333/54 , Y02A50/386 , Y02A50/401 , Y02A50/41 , Y02A50/412 , Y02A50/57 , Y02A50/58
Abstract: An anti-IL-23 antibody, including isolated nucleic acids that encode at least one anti-IL-23 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
-
公开(公告)号：US09752126B2
公开(公告)日：2017-09-05
申请号：US14963436
申请日：2015-12-09
Applicant: Janssen Biotech, Inc.
Inventor： Alireza Rezania , Benjamin Fryer
IPC: C12N5/071
CPC classification number: C12N5/0676 , C12N2501/115 , C12N2501/117 , C12N2501/155 , C12N2501/16 , C12N2501/39 , C12N2501/405 , C12N2501/41 , C12N2501/70 , C12N2501/998 , C12N2506/02
Abstract: The present invention provides a method for increasing the expression of MAFA in cells expressing markers characteristic of the pancreatic endocrine lineage comprising the steps of culturing the cells expressing markers characteristic of the pancreatic endocrine lineage in medium comprising a sufficient amount of a cyclin-dependent kinase inhibitor to cause an increase in expression of MAFA.
-
公开(公告)号：US20170233461A1
公开(公告)日：2017-08-17
申请号：US15584235
申请日：2017-05-02
Applicant: New York University , Janssen Biotech, Inc.
Inventor： Victor J. TORRES , Randall J. BREZSKI , Anthony LYNCH , William STROHL , Brian WHITAKER , Mark CHIU , Peter T. BUCKLEY , Keri DORN , Michelle KINDER
CPC classification number: C07K16/1271 , C07K14/78 , C07K2317/30 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2318/00 , C07K2319/70 , G01N33/56938 , G01N2469/10
Abstract: The present application generally relates to multi-specific molecules that bind to multiple bacterial virulence factors, methods for producing these binding molecules, and the use of these binding molecules to treat bacterial infections. In particular, the binding molecules comprise at least two binding domains, preferably an antibody or antibody fragment and an alternative scaffold. The first binding domain is capable of binding to a glycosylated staphylococcal surface protein, preferably an SDR-containing protein. The second binding domain is capable of binding to a staphylococcal leukotoxin, preferably LukAB, LukD or LukE. These multi-specific binding compounds have killing activity against staphylococci and, thus, can be used in the treatment and/or amelioration of a Staphylococcus infection, including methicillin-resistant Staphylococcus aureus.
-
-
-
-
-
-
-
-
-
Search Results
1019
records
(took 0.054 seconds)
